Clinical Trial Update: Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating oral ARV-1801 in combination with IV ceftazidime or meropenem for hospitalized melioidosis patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melioidosis

Drugs mentioned

• ARV-1801
• Meropenem (Meropenem)
• ceftazidime (ceftazidime)

Snippet

Sponsor: Arrevus Inc. | Conditions: Melioidosis | Phase 2 | Status: COMPLETED